Erratum to Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir Disposition [Clinical Pharmacokinetics, 10.1007/s40262-014-0160-3];Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir Disposition

Clinical Pharmacokinetics

Volumn 53, Issue 9, 2014, Pages 825-836

  Hu, Zhe Yi ^a   Edginton, Andrea N ^b   Laizure, S Casey ^a   Parker, Robert B ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIVIRUS AGENT; CARBOXYLESTERASE; CES1 PROTEIN, HUMAN; OSELTAMIVIR;

ADULT; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; COMPUTER SIMULATION; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; METABOLISM;

ADULT; ANTIVIRAL AGENTS; CARBOXYLIC ESTER HYDROLASES; COMPUTER SIMULATION; HUMANS; MALE; MODELS, BIOLOGICAL; OSELTAMIVIR; POLYMORPHISM, GENETIC;

EID: 84929131979     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0174-x     Document Type: Erratum

References (58)

1. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. Current progress on esterases: from molecular structure to function. Drug Metab Dispos. 2002;30(5):488–93.
2. Laizure SC, Herring VL, Hu Z, Witbrodt K, Parker RB. The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy. 2013;33(2):210–22.
3. Tarkiainen EK, Backman JT, Neuvonen M, Neuvonen PJ, Schwab M, Niemi M. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther. 2012;92(1):68–71.
4. Zhu HJ, Markowitz JS. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos. 2009;37(2):264–7.
5. Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 2013;344(3):665–72.
6. Holstein A, Beil W, Kovacs P. CYP2C metabolism of oral antidiabetic drugs—impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab Toxicol. 2012;8(12):1549–63.
7. Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther. 2007;81(2):298–304.
8. Bourland JA, Martin DK, Mayersohn M. Carboxylesterase-mediated transesterification of meperidine (Demerol) and methylphenidate (Ritalin) in the presence of [2H6]ethanol: preliminary in vitro findings using a rat liver preparation. J Pharm Sci. 1997;86(12):1494–6.
9. Hu ZY, Laizure SC, Herring VL, Parker RB. Identification of alcohol-dependent clopidogrel metabolites using conventional liquid chromatography/triple quadrupole mass spectrometry. Rapid Commun Mass Spectrom. 2014;28(11):1285–92.
10. Parker RB, Laizure SC. The effect of ethanol on oral cocaine pharmacokinetics reveals an unrecognized class of ethanol-mediated drug interactions. Drug Metab Dispos. 2010;38(2):317–22.
11. Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, et al. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2007;81(3):346–53.
12. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther. 2006;319(3):1467–76.
13. Lewis JP, Horenstein RB, Ryan K, O’Connell JR, Gibson Q, Mitchell BD, et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics. 2013;23(1):1–8.
14. Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127(13):1404–12.
15. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89(2):259–67.
16. Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro–in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012;92(1):50–61.
17. Hu ZY, Laizure SC, Meibohm B, Herring VL, Parker RB. Simple and sensitive assay for quantification of oseltamivir and its active metabolite oseltamivir carboxylate in human plasma using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry: improved applicability to pharmacokinetic study. J Pharm Biomed Anal. 2013;72:245–50.
18. Brennan BJ, Davies B, Cirrincione-Dall G, Morcos PN, Beryozkina A, Chappey C, et al. Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers. Antimicrob Agents Chemother. 2012;56(9):4729–37.
19. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999;37(6):471–84.
20. Wattanagoon Y, Stepniewska K, Lindegardh N, Pukrittayakamee S, Silachamroon U, Piyaphanee W, et al. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):945–52.
21. Zhao Y, Hu ZY. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. Br J Pharmacol. 2014;171(4):1043–53.
22. Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J Pharm Sci. 2011;100(12):5324–45.
23. Thelen K, Coboeken K, Willmann S, Dressman JB, Lippert J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms. J Pharm Sci. 2012;101(3):1267–80.
24. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259–76.
25. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238–57.
26. Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res. 2007;24(5):918–33.
27. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther. 2006;319(3):1477–84.
28. Imai T. Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet. 2006;21(3):173–85.
29. Punt A, Paini A, Boersma MG, Freidig AP, Delatour T, Scholz G, et al. Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats. Toxicol Sci. 2009;110(2):255–69.
30. Meyer M, Schneckener S, Ludewig B, Kuepfer L, Lippert J. Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab Dispos. 2012;40(5):892–901.
31. Cer RZ, Mudunuri U, Stephens R, Lebeda FJ. IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding. Nucleic Acids Res. 2009;37:441–5.
32. Li L, Zhao Y, Du F, Yang J, Xu F, Niu W, et al. Intestinal absorption and presystemic elimination of various chemical constituents present in GBE50 extract, a standardized extract of Ginkgo biloba leaves. Curr Drug Metab. 2012;13(5):494–509.
33. Jones AW. Pharmacokinetic and pharmacodynamic interactions between alcohol and other drugs. In: Ashraf M, Lionel R, editors. Handbook of drug interactions: a clinical and forensic guide. 2nd ed. New York: Humana Press; 2012.
34. Wilkinson PK, Sedman AJ, Sakmar E, Kay DR, Wagner JG. Pharmacokinetics of ethanol after oral administration in the fasting state. J Pharmacokinet Biopharm. 1977;5(3):207–24.
35. Yanjiao X, Chengliang Z, Xiping L, Tao W, Xiuhua R, Dong L. Evaluation of the inhibitory effects of antihypertensive drugs on human carboxylesterase in vitro. Drug Metab Pharmacokinet. 2013;28(6):468–74.
36. Zhu HJ, Appel DI, Peterson YK, Wang Z, Markowitz JS. Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. Toxicology. 2010;270(2–3):59–65.
37. Rhoades JA, Peterson YK, Zhu HJ, Appel DI, Peloquin CA, Markowitz JS. Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug–drug interactions. Pharm Res. 2012;29(4):972–82.
38. Hatfield MJ, Tsurkan LG, Hyatt JL, Edwards CC, Lemoff A, Jeffries C, et al. Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza (“Danshen”). J Nat Prod. 2013;76(1):36–44.
39. Tsurkan LG, Hatfield MJ, Edwards CC, Hyatt JL, Potter PM. Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. Chem Biol Interact. 2013;203(1):226–30.
40. Dean RA, Christian CD, Sample RH, Bosron WF. Human liver cocaine esterases: ethanol-mediated formation of ethylcocaine. FASEB J. 1991;5(12):2735–9.
41. Farre M, de la Torre R, Gonzalez ML, Teran MT, Roset PN, Menoyo E, et al. Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism. J Pharmacol Exp Ther. 1997;283(1):164–76.
42. Song N, Parker RB, Laizure SC. Cocaethylene formation in rat, dog, and human hepatic microsomes. Life Sci. 1999;64(23):2101–8.
43. Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Bell GH, Anderson ER, et al. Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans. Drug Metab Dispos. 2013;41(1):197–205.
44. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. J Antimicrob Chemother. 2010;65(Suppl 2):ii11–24.
45. Izumi Y, Tokuda K, O’Dell KA, Zorumski CF, Narahashi T. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett. 2007;426(1):54–8.
46. Jones M, Hama R, Jefferson T, Doshi P. Neuropsychiatric adverse events and oseltamivir for prophylaxis. Drug Saf. 2012;35(12):1187–8 author reply 8–90.
47. Bahar FG, Ohura K, Ogihara T, Imai T. Species difference of esterase expression and hydrolase activity in plasma. J Pharm Sci. 2012;101(10):3979–88.
48. Einolf HJ, Chen L, Fahmi OA, Gibson CR, Obach RS, Shebley M, et al. Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clin Pharmacol Ther. 2014;95(2):179–88.
49. Einolf HJ. Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica. 2007;37(10–11):1257–94.
50. Perdaems N, Blasco H, Vinson C, Chenel M, Whalley S, Cazade F, et al. Predictions of metabolic drug-drug interactions using physiologically based modelling: two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet. 2010;49(4):239–58.
51. Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, et al. Evaluation of various static in vitro–in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug. Clin Pharmacol Ther. 2014;95(2):189–98.
52. Parrott N, Davies B, Hoffmann G, Koerner A, Lave T, Prinssen E, et al. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin Pharmacokinet. 2011;50(9):613–23.
53. Hsu V, de L T Vieria M, Zhao P, Zhang L, Zheng JH, Nordmark A, et al. Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. Clin Pharmacokinet. 2014;53(3):283–93.
54. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008;82(6):1241–8.
55. Jonsson KA, Jones AW, Bostrom H, Andersson T. Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. Eur J Clin Pharmacol. 1992;42(2):209–12.
56. Jones AW, Hahn RG, Stalberg HP. Distribution of ethanol and water between plasma and whole blood; inter- and intra-individual variations after administration of ethanol by intravenous infusion. Scand J Clin Lab Investig. 1990;50(7):775–80.
57. Umulis DM, Gurmen NM, Singh P, Fogler HS. A physiologically based model for ethanol and acetaldehyde metabolism in human beings. Alcohol. 2005;35(1):3–12.
58. DrugBank database. http://www.drugbank.ca. Accessed 6 Mar 2013.